Contraceptive Patch Maker Agile Recapitalizes With $45 Million Venture Round
This article was originally published in The Pink Sheet Daily
Executive Summary
Agile said in 2008 its lead product was ready for Phase III trials. Those trials might start soon, now that the firm has found new backers.
You may also be interested in...
Transdermal Delivery Trumps Advisory Panel Concerns About Blood Clots With J&J’s Ortho Evra
With an eye toward keeping the contraceptive patch as an alternative to birth control pills, the Reproductive Health Drugs and Drug Safety and Risk Management Committees voted 19-5 on Dec. 9 that the benefits of the contraceptive patch outweigh its risks.
Financings Of The Fortnight Follows The Money Wherever It Goes
Are VCs looking beyond biopharma to put money into areas like health services and diagnostics? Plus updates on Castlight, Agile Therapeutics, Otonomy, and more.
Financings Of The Fortnight Follows The Money Wherever It Goes
Are VCs looking beyond biopharma to put money into areas like health services and diagnostics? Plus updates on Castlight, Agile Therapeutics, Otonomy, and more.